Oramed Pharmaceuticals Investor and Analyst Breakfast Transcript, Monday, November 18, 2019

Oramed Pharmaceuticals Inc. held an investor event and conference call to review the positive results from the initial cohort of the Phase IIb trial evaluating the efficacy and safety of its lead oral insulin candidate, ORMD-0801, on Monday, November 18, 2019.

To listen to a recording of the event please click here.

To view the slides, please click here.